Goldman Sachs Group Inc. Sells 214,630 Shares of Sanofi (NASDAQ:SNY)

Goldman Sachs Group Inc. cut its holdings in Sanofi (NASDAQ:SNYFree Report) by 8.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,350,669 shares of the company’s stock after selling 214,630 shares during the period. Goldman Sachs Group Inc. owned 0.09% of Sanofi worth $116,899,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Boston Partners boosted its holdings in Sanofi by 1.9% in the 4th quarter. Boston Partners now owns 13,032,746 shares of the company’s stock valued at $648,617,000 after purchasing an additional 245,682 shares during the period. Morgan Stanley grew its holdings in shares of Sanofi by 4.6% during the 3rd quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after purchasing an additional 323,968 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Sanofi by 29.8% during the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock valued at $152,279,000 after purchasing an additional 651,756 shares during the period. Natixis Advisors L.P. raised its stake in shares of Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after purchasing an additional 346,563 shares in the last quarter. Finally, Brandes Investment Partners LP boosted its position in shares of Sanofi by 64.6% during the 4th quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after acquiring an additional 694,957 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

Separately, lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $55.00.

Read Our Latest Report on SNY

Sanofi Trading Down 2.7 %

Shares of Sanofi stock traded down $1.28 on Friday, hitting $46.25. 3,797,354 shares of the company’s stock traded hands, compared to its average volume of 1,817,849. The firm’s 50-day moving average price is $48.32 and its two-hundred day moving average price is $48.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock has a market capitalization of $117.00 billion, a PE ratio of 23.24, a price-to-earnings-growth ratio of 1.49 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.96. The company had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. On average, research analysts expect that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 6th. Investors of record on Friday, May 10th were given a $1.478 dividend. The ex-dividend date was Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is currently 74.37%.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.